Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

CV Therapeutics advances CVT-510 into phase II clinical trials

Dec. 10, 1999

Preparation and use of inhibitors of sodium-dependent Cl-/HCO3- exchange

Dec. 8, 1999

Chiron and Scios complete FGF agreement

Dec. 8, 1999

New cardioselective K(ATP) channel blocker inhibits ventricular fibrillation in ischemic rat model

Dec. 6, 1999

Highly potent inhibitor of PDGF-induced SMC proliferation discovered at Japan Energy

Dec. 3, 1999

Wakunaga identifies potent and selective chymase inhibitor

Dec. 3, 1999

Chiron and Searle plan pivotal phase III trial for sepsis compound

Dec. 3, 1999

Studies using new transgenic rat model illustrate role of CETP in atherosclerosis

Dec. 2, 1999

Kyowa Hakko prepares antiproliferative agents that interact with the PDGF receptor

Dec. 2, 1999

V1A/AT1 receptor antagonist combinations for cardiovascular disorders

Dec. 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...